Neuronetics, Inc. (STIM) Cash Flow Statement

NASDAQ: STIMOperating cash, capex, free cash flow and buybacks.

Where STIM’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$20.4M
Capital expenditures
$801,000
0.5% of revenue
Free cash flow
−$21.2M
−14.2% margin
Returned to shareholders
$1.7M
Change in cash
$14.7M
cash at year-end $34.1M
Borrowing: $9.8MBorrowing$9.8MShares issued: $29.0MShares issued$29.0MCash used in operations: $20.4MCash used in operations$20.4M · 53%Share buybacks: $1.7MShare buybacks$1.7M · 4%Other financing: $1.2MOther financing$1.2M · 3%Added to cash: $14.7MAdded to cash$14.7M · 38%Capital expenditures: $801,000Capital expenditures$801,000 · 2%$38.8M
Cash from operations
−$20.4M
Capital expenditures
−$801,000
Share buybacks (net)
−$1.7M
Net borrowing (repayment)
+$9.8M
Shares issued
+$29.0M
Other financing
−$1.2M
Change in cash
$14.7M

Drawn to scale: where the cash came from and how it was used. Hover for values.

STIM operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

STIM cash flow trends, 2016–2025

Neuronetics, Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$8.5M2016−$20.4M2025—
Capital expenditures$324,0002016$801,0002025+10.6%/yr
Free cash flow−$8.9M2016−$21.2M2025—
Free cash flow margin−25.9%2016−14.2%2025+11.7 pts
Stock-based compensation$161,0002016$6.8M2025+51.7%/yr
Share buybacks (net)$02016$1.7M2025—
Capex / revenue0.9%20160.5%2025−0.4 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

STIM cash flow by activity

OperatingInvestingFinancingChange in cash

STIM net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

STIM cash flow statement

Neuronetics, Inc. annual cash flow statement
2025202420232022202120202019201820172016
Operating activities
Net income−$39.1M−$43.7M−$30.2M−$37.2M−$31.2M−$27.5M−$29.0M−$24.1M−$16.1M−$11.2M
Depreciation & amortization$3.5M$2.1M$2.0M$1.6M$1.1M$941,000$1.1M$882,000$596,000$673,000
Stock-based compensation$6.8M$5.6M$7.3M$8.7M$7.9M$4.4M$3.4M$1.7M$496,000$161,000
Change in working capital$6.6M−$6.8M−$14.1M−$5.1M−$6.6M−$8.3M−$6.9M−$1.6M$3.2M$1.3M
Other non-cash items$1.9M$11.9M$2.9M$1.1M$918,000$2.0M$976,000$2.5M$667,000$514,000
Cash from operating activities−$20.4M−$31.0M−$32.0M−$30.7M−$28.0M−$28.4M−$30.5M−$20.6M−$11.1M−$8.5M
Investing activities
Capital expenditures−$801,000−$1.5M−$2.4M−$3.3M−$2.4M−$730,000−$813,000−$1.0M−$594,000−$324,000
Investments (net)—−$2.4M−$1.3M$10.0M−$9.8M−$730,000−$813,000−$1.0M−$594,000−$324,000
Acquisitions & other investing$0$1.5M$2.4M$0$2.4M$730,000$813,000$1.0M$594,000$324,000
Cash from investing activities−$801,000−$2.4M−$1.3M$6.7M−$9.8M−$730,000−$813,000−$1.0M−$594,000−$324,000
Financing activities
Share repurchases & issuance (net)−$1.7M$0$0$298,000—$690,000$2.4M$97.0M$14.9M$67,000
Net borrowing (repayment)$9.8M−$2.5M$23.8M−$91,000$0$1.7M$2.5M$2.5M$10.0M$5.0M
Shares issued$29.0M$0$0$0$81.0M$0$0$100.0M$0$0
Other financing−$1.2M−$4.3M−$1.1M$0$2.0M$0−$2.5M−$102.5M−$1.0M−$171,000
Cash from financing activities$35.9M−$6.8M$22.7M$207,000$83.0M$2.4M$2.4M$97.0M$23.8M$4.9M
Summary
Net change in cash$14.7M−$40.2M−$10.7M−$23.8M$45.2M−$26.8M−$28.9M$75.4M$12.1M−$4.0M
Cash at end of period$34.1M$19.5M$59.7M$70.3M$94.1M$49.0M$75.7M$104.6M$29.1M$17.0M
Free cash flow−$21.2M−$32.5M−$34.4M−$34.0M−$30.3M−$29.1M−$31.3M−$21.6M−$11.7M−$8.9M
Free cash flow margin−14.2%−43.3%−48.2%−52.2%−54.8%−59.1%−49.9%−40.9%−29.0%−25.9%
Capex / revenue0.5%2.0%3.3%5.0%4.3%1.5%1.3%1.9%1.5%0.9%

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

STIM cash generation

In fiscal 2025 (ended December 31, 2025), Neuronetics generated -$20.4 million of cash from operations and spent $0.8 million on capital expenditures, leaving free cash flow of -$21.2 million, −14.2% of revenue. It returned $1.7 million to shareholders through dividends ($0) and net share buybacks ($1.7 million). Cash and equivalents rose by $14.7 million over the year.

Related: STIM income statement, STIM balance sheet. See the STIM stock overview for the latest quote and news.

STIM cash flow FAQ

What is Neuronetics's free cash flow?

Neuronetics's free cash flow was -$21.2 million in fiscal 2025: -$20.4 million of operating cash flow minus $0.8 million of capital expenditures It was -$32.5 million a year earlier..

How much cash does Neuronetics generate from operations?

Neuronetics generated -$20.4 million of cash from operating activities in fiscal 2025.

How much does Neuronetics spend on capital expenditures?

Neuronetics spent $0.8 million on capital expenditures in fiscal 2025, 0.5% of revenue, compared with $1.5 million the year before.

How much stock does Neuronetics buy back?

Neuronetics spent $1.7 million on net share repurchases in fiscal 2025.

Medical Devices: cash flow